Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

2030 - Recurrence pattern and its prognostic impact following definitive chemo-radiotherapy in stage III non-small cell lung cancer


08 Oct 2016


Poster Display


Maria Saigi Morgui


Annals of Oncology (2016) 27 (6): 411-415. 10.1093/annonc/mdw382


M. Saigi Morgui1, A.J. Rullan Iriarte1, M. Bergamino1, A. Navarro2, M.M. Arnaiz2, R. Palmero1, M. Plana Serrahima1, C. Mesía1, S. Padrones3, S. Aso3, J. Ruffinelli Rodriguez1, V. Navarro4, I. Brao5, E. Nadal1, F. Cardenal Alemany1

Author affiliations

  • 1 Medical Oncology, Thoracic Oncology Unit, Institut Català d'Oncologia Hospital Duran i Reynals, 08908 - Barcelona/ES
  • 2 Radiotherapy Oncology, Thoracic Oncology Unit, Institut Català d'Oncologia Hospital Duran i Reynals, 08908 - Barcelona/ES
  • 3 Pneumologist, Thoracic Oncology Unit, Hospital Universitari de Bellvitge, 08907 - Barcelona/ES
  • 4 Biostatistics For Medical Oncology, Institut Catala de Oncologia, 08907 - Barcelona/ES
  • 5 Nurse Specialist, Thoracic Oncology Unit, Institut Català d'Oncologia Hospital Duran i Reynals, 08908 - Barcelona/ES


Abstract 2030


The influence of the recurrence pattern on outcome of patients (pts) with stage III NSCLC following definitive chemo-radiotherapy (CRT) has been scarcely addressed in the literature. The aim of this study was to assess the relevance of oligoprogression (OP) in this clinical setting.


Pts diagnosed with stage III NSCLC who underwent concurrent CRT from 2010 to 2014 at the Catalan Institute of Oncology were retrospectively studied.The recurrence pattern at the first progression was recorded. OPwas defined as a single metastatic site with no more than 3 lesions. Overall Survival (OS),Progression-Free Survival (PFS) and Postprogression OS (PPOS) were plotted using the Kaplan Meiermethod and multivariate Cox proportional hazards models were developed.


From 171 pts: median age 62 (37-81),male 87%; ECOG ≤ 1 92%; smoking status: current 49%, former 46%, never 5%; histology: adenocarcinoma (ADC) 34%,squamous (SCC) 43%, NSCLC (NOS + large cell) 23%; Stage:IIIA 51%, IIIB 49%; cN0-1 21%, cN2 60%, cN3 19%.Platinum doublet CT: Cisplatin 62%, Carboplatin 38%. Rate between 60 and 70 Gy:94%. At a median follow-up of 48months (m), 108 patients relapsed (63%), the mPFS was 13m (95% CI 10-16) and the mOS was 28m (95% CI 22-34). Recurrence pattern: Distant (D) 36%; Loco-regional (LR) 33%;both(LR + D) 30%.Twenty-five pts (23%) developed OP (48% ADC, 52% SCC) and the organs involved were17 visceral, 3 lymph nodes, 4 brain and 1 bone. Treatments performed in OP pts: 4 surgery, 4 stereotactic radiosurgery, 1 salvage CRT, 3 RT (WBRTx2 + 1 RTE 20 Gy), 9 CT, 4 none. From all pts who progressed (n = 108)mOS was 26m for those who received 2nd line treatment (n = 77,72%), vs 13m for those without treatment (p 


In this cohort, the frequency of OP was remarkable and associated with improved OS. Pts with OP that might benefit from salvage therapies should be better characterized and proactively detected during follow-up after definitive CRT.

Clinical trial identification

Legal entity responsible for the study

Institut Català d'Oncologia


Institut Català d'Oncologia


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings